Corpus Intelligence IC Memo — ALFRED I DUPONT HOSP FOR CHILDREN 2026-04-26 17:25 UTC
IC Memo — ALFRED I DUPONT HOSP FOR CHILDREN
Investment Committee Memorandum | DE | 206 beds | Grade B | EBITDA uplift $51.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ALFRED I DUPONT HOSP FOR CHILDREN

CCN 083300 | NEW CASTLE, DE | 206 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

ALFRED I DUPONT HOSP FOR CHILDREN is a 206-bed safety-net/medicaid heavy in NEW CASTLE, DE with $694.0M in net patient revenue and a 17.3% operating margin. The hospital serves a payer mix of 0.2% Medicare, 31.4% Medicaid, and 68.3% commercial.

Thesis: Platform Growth. Our ML models identify $51.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 17.3% to 24.6% (+736bps).

Net Revenue HCRIS$694.0M
Current EBITDA COMPUTED$120.0M
Operating Margin COMPUTED17.3%
Occupancy HCRIS76.4%
Revenue / Bed COMPUTED$3.4M
Net-to-Gross HCRIS42.0%
Distress Probability ML46.2%

2. Market Context & Competitive Position

14
DE Hospitals
0.7%
State Median Margin
1914
Comparable Hospitals

DE has 14 Medicare-certified hospitals with a median operating margin of 0.7%. The target's margin of 17.3% places it above the state median. Among 1914 size-comparable peers (103-412 beds), the median margin is -3.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (103-412), prioritizing same-state peers. 1914 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ALFRED I DUPONT HOSP FOR CHILD (Target)DE206$694.0M17.3%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
MAYO CLINIC HOSPITALAZ315$2.25B1.4%
RAINBOW BABIES & CHILDRENS HOSOH231$2.22B-5.0%
EASTERN MAINE MEDICAL CENTERME352$2.05B48.1%
ARTHUR G JAMES CANCER HOSPITALOH356$1.95B21.0%
MOFFITT CANCER CENTERFL218$1.91B16.0%
UCI MEDICAL CENTERCA397$1.90B-2.5%
BANNER ESTRELLA MEDICAL CENTERAZ317$1.84B79.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $51.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$14.6M+210bp18mo
Cost to Collect4.5%2.5%$13.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$13.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$8.4M+122bp9mo
Clean Claim Rate88.0%96.0%$444K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$14.6M
Cost to Collect
$13.9M
Denial Rate Reduction
$13.7M
A/R Days Reduction
$8.4M
Clean Claim Rate
$444K
Total EBITDA Uplift$51.1M
Current EBITDA$120.0M
+ RCM Uplift+$51.1M
Pro Forma EBITDA$171.0M
Current Margin17.3%
Pro Forma Margin24.6%
WC Released (1x)$26.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$184.6M$1.30B7.06x47.8%
Base (11x exit)10.0x11.0x$184.6M$1.49B8.09x51.9%
Bull Case9.0x11.0x$166.1M$1.72B10.36x59.6%
Bull (12x exit)9.0x12.0x$166.1M$1.93B11.60x63.3%
Bear Case11.0x10.0x$203.0M$986.8M4.86x37.2%
Bear (11x exit)11.0x11.0x$203.0M$1.15B5.67x41.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (31.4%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 1914 hospitals with 103-412 beds
  • Same-state prioritization (n=8)
  • Comp margins: P25=-13.8% / P50=-3.8% / P75=6.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.